A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of GRN163L in Patients With Chronic Lymphoproliferative Disease
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 8
- 主要终点
- Safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or recommended phase II dose of GRN163L in patients with relapsed or refractory chronic lymphoproliferative disease
研究概览
简要总结
The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease.
详细描述
Imetelstat Sodium (GRN163L) is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in antineoplastic effects. High telomerase levels and short telomere lengths correlate with other markers of poor prognosis in patients with chronic lymphoproliferative disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or older
- •Male or female
- •Chronic lymphoproliferative disease with related biology or similar clinical pattern to B-Cell Leukemia (CLL)including: small lymphocytic lymphoma (SLL), T cell prolymophocytic leukemia (T-PLL), B cell prolymphocytic leukemia (B-PLL), mantle cell lymphoma or other non-Hodgkins lymphoma in leukemic phase (peripheral blood circulating malignant cells present), Waldenstrom's macroglobulinemia
- •Must have relapsed from or be refractory to prior therapeutic regimens
- •Patients with CLL or SLL must have received at least one prior purine analogue-based chemotherapy regimen (eg, fludarabine, pentostatin or cladribine)
- •If previously treated with an anthracycline, anthracenedione, or trastuzumab, must have left ventricular ejection fraction > 50%
- •ECOG performance status 0-2
- •Life expectancy 3 months or greater
排除标准
- •Pregnant or lactating women
- •Active 2nd malignancy or history of another malignancy within 2 years, except:treated, non-melanoma skin cancer,treated breast or cervical carcinoma in situ,or resected T1a or b prostate cancer
- •Chemotherapeutic agents within 4 weeks prior to study
- •High dose CTX with stem cell support within 6 months prior to study
- •Signal transduction inhibitors,or monoclonal antibodies within 4 weeks prior to study
- •Immunotherapy or biological response modifiers within 4 weeks prior to study
- •Systemic hormonal therapy within 4 weeks prior to study
- •Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study
- •Radiotherapy within 4 weeks prior to study
- •Active autoimmune disorder
- •Central nervous system or leptomeningeal involvement
- •Clinically significant cardiovascular disease
- •Known HIV infection
- •Serious/active infection
- •Surgical procedure within 2 weeks
研究组 & 干预措施
open label
Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours
干预措施: GRN163L (Drug)
结局指标
主要结局
Safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or recommended phase II dose of GRN163L in patients with relapsed or refractory chronic lymphoproliferative disease
时间窗: First 3 weeks
次要结局
- PK and PD(Measured in the first 6 weeks)